<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2981">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01682915</url>
  </required_header>
  <id_info>
    <org_study_id>201204071RIC</org_study_id>
    <nct_id>NCT01682915</nct_id>
  </id_info>
  <brief_title>Structural and Functional Connectivity of Frontostriatal and Frontoparietal Networks as Endophenotypes of ADHD</brief_title>
  <official_title>Structural and Functional Connectivity of Frontostriatal and Frontoparietal Networks as Endophenotypes of Attention-deficit Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Attention deficit/hyperactivity disorder (ADHD) is a common, impairing, clinically and&#xD;
      genetically heterogeneous neuropsychiatric disorder with lifelong executive dysfunctions. The&#xD;
      ultimate goal of this 3-year case-control imaging genomic study with unaffected siblings and&#xD;
      typically developing (TD) children as controls is to identify useful imaging endophenotype&#xD;
      for ADHD by investigating the structural connectivity, as assessed by diffusion spectrum&#xD;
      imaging (DSI), and functional connectivity, as assessed by resting-state fMRI (rsfMRI) of&#xD;
      brain regions related to cognitive/executive controls with regards to the ADHD status and the&#xD;
      presence of dopamine transporter gene variants (DAT1).&#xD;
&#xD;
      Specific Aims:&#xD;
&#xD;
        1. to validate the executive functions, visuospatial memory, and structural and functional&#xD;
           connectivity in frontostriatal, and frontoparietal circuitries as effective&#xD;
           neurocognitive endophenotypes;&#xD;
&#xD;
        2. to correlate the data from structural and functional connectivity, neuropsychology, and&#xD;
           ADHD core symptoms stratifying by the presence of ADHD, proband-unaffected sibling&#xD;
           dyads, and the presence of DAT1 variant; and&#xD;
&#xD;
        3. To investigate reported candidate genes, in addition to DAT1 variant, related to&#xD;
           dopamine and noradrenergic neurotransmitter systems in the association with&#xD;
           neurocognitive endophenotypes such as DRD1, DRD2, DRD4, DRD5, DBH, MAO-A, ADRA2A,&#xD;
           ADRA2C, NET, and COMT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The sample (n=240, 8 groups, ages 10-20, IQ &gt; 80) consists of (1) 30 ADHD probands with DAT1&#xD;
      variants, (2) 30 same-sex unaffected siblings, (3) 30 ADHD probands without DAT1 gene&#xD;
      variants, who were age-, sex-, and IQ-matched to Group 1, (4) 30 same-sex unaffected siblings&#xD;
      of Group 3, (5) 30 age-, sex- and IQ-matched TD controls for each of 4 groups (Groups 1, 2, 3&#xD;
      &amp; 4).&#xD;
&#xD;
      The assessments include psychiatric interviews, self-administered questionnaires (CBCL and&#xD;
      SNAP-IV for ADHD and behavioral problems; the SAICA for school and social function),&#xD;
      neurocognitive assessments (WISC-III-R or WAIS-III for intelligence, Conner's CPT for&#xD;
      sustained attention, inhibition, and vigilance, CANTAB for executive functions and&#xD;
      visuo-spatial memory), and MRI assessments (Structural MRI, DSI and rsfMRI).&#xD;
&#xD;
      Brain Imaging: (1) Structural MRI (T1- and T2-weighted images), DSI and rsfMRI data will be&#xD;
      acquired on a 3T MRI system with a 32-channel head coil. DSI employs a pulsed-gradient&#xD;
      spin-echo echo planar imaging (EPI) sequence by applying 102 diffusion gradient vectors and&#xD;
      the maximum diffusion sensitivity = 4000 s/mm2, and rsfMRI is a 6-minute scan using a&#xD;
      gradient-echo EPI sequence with 180 volumes. (2) Structural connectivity analysis: DSI&#xD;
      tractography will be performed using in-house software (DSI studio,&#xD;
      http://dsi-studio.labsolver.org/Home). Tracts-of-interest in the frontostriatal circuit and&#xD;
      the frontoparietal circuit will be identified, and tract-specific analysis will be used to&#xD;
      analyze the microstructural integrity along individual tract bundles. (3) Functional&#xD;
      connectivity analysis: SPM8 program and in-house MATLAB codes will be used for analyses of&#xD;
      rsfMRI data. Region-of-interests (ROIs) will be placed in the nodes of the corresponding&#xD;
      circuits according to an anatomical template (WFU_PickAtlas 3.03). These ROIs will serve for&#xD;
      tract determination in the tractography procedure and for seed regions in which BOLD signals&#xD;
      are extracted for regression analysis among nodes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2012</start_date>
  <completion_date type="Actual">July 31, 2015</completion_date>
  <primary_completion_date type="Actual">July 31, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">240</enrollment>
  <condition>Attention Deficit/Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Group 1: ADHD+DAT1, Probands</arm_group_label>
    <description>30 ADHD probands with DAT1 variants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: ADHD+DAT1, Unaffected sibling</arm_group_label>
    <description>30 same-sex unaffected siblings of Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: ADHD Drug-na誰ve, Probands</arm_group_label>
    <description>30 ADHD probands without DAT1 gene variants, who were age-, sex-, and IQ-matched to Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: ADHD Drug-na誰ve, unaffected sibling</arm_group_label>
    <description>30 same-sex unaffected siblings of Group 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched controls</arm_group_label>
    <description>30 age-, sex- and IQ-matched TD controls for each of 4 groups</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The sample (n=240, 8 groups, ages 10-20, IQ &gt; 80) consists of (1) 30 ADHD probands with&#xD;
        DAT1 variants, (2) 30 same-sex unaffected siblings, (3) 30 ADHD probands without DAT1 gene&#xD;
        variants, who were age-, sex-, and IQ-matched to Group 1, (4) 30 same-sex unaffected&#xD;
        siblings of Group 3, (5) 30 age-, sex- and IQ-matched TD controls for each of 4 groups&#xD;
        (Groups 1, 2, 3 &amp; 4).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ADHD+DAT1 groups: Subjects aged 12-20, who have clinical diagnosis of ADHD according&#xD;
             to the DSM-IV diagnostic criteria and who have risk alleles of DAT1 gene, regardless&#xD;
             of having same-sex unaffected siblings or the drug-na誰ve status.&#xD;
&#xD;
          -  ADHD drug-na誰ve groups: Subjects aged 12-20, who have clinical diagnosis of ADHD&#xD;
             according to the DSM-IV diagnostic criteria, who do not have risk alleles of DAT1&#xD;
             gene, who have the same-sex unaffected siblings and who have never been treated by&#xD;
             medication for treating ADHD.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  These subjects will be excluded from the study if they have any of the following&#xD;
             criteria: (1) Comorbidity with DSM-IV-TR diagnosis of pervasive developmental&#xD;
             disorder, schizophrenia, schizoaffective disorder, delusional disorder, other&#xD;
             psychotic disorder, organic psychosis, schizotypal personality disorder, bipolar&#xD;
             disorder, depression, severe anxiety disorders or substance use; (2) With&#xD;
             neurodegenerative disorder, epilepsy, involuntary movement disorder, congenital&#xD;
             metabolic disorder, brain tumor, history of severe head trauma, and history of&#xD;
             craniotomy; (3)With visual or hearing impairments, or motor disability which may&#xD;
             influence the process of MRI assessment; and (4) Full-scale IQ lower than 80. In&#xD;
             addition, if the control subjects have ODD or CD, they will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Taiwan Univeristy Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2012</study_first_submitted>
  <study_first_submitted_qc>September 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2012</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Taiwan University Hospital</investigator_affiliation>
    <investigator_full_name>Statistical Center, NTUHCTC</investigator_full_name>
    <investigator_title>Susan Shur-Fen Gau</investigator_title>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>endophenotype</keyword>
  <keyword>executive function</keyword>
  <keyword>diffusion spectrum imaging</keyword>
  <keyword>resting-state fMRI</keyword>
  <keyword>frontostriatal and frontoparietal circuitries</keyword>
  <keyword>DAT1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

